NY-ESO-1-SPECIFIC TCR-ENGINEERED T CELL IMMUNOTHERAPY FOR TRIPLE NEGATIVE BREAST CANCER

$828,577FY2016Defense Health AgencyDOD

The Methodist Hospital Research Institute, Houston TX

Investigators